Just Released: Q1 2019 Regenerative Medicine Sector Data Report

ARM today released its most recent quarterly data report, offering an in-depth look at cell therapy, gene therapy, tissue engineering, and broader global regenerative medicine sector trends and metrics in the first quarter of 2019.

By further curating information provided by ARM’s data partner Informa, the quarterly data report details industry-specific statistics compiled from 917 cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities

Key findings include:

• Globally, companies active in gene and cell therapies and other regenerative medicines raised $2.2 billion in the first quarter of 2019. The report also includes financial data broken out by technology type and financing type.
• There were 1,060 clinical trials underway worldwide at the close of the first quarter of 2019, with more than 58% of those in oncology and 6% in cardiovascular disorders. The report also includes figures on clinical trials by phase and indication, as well as by technology type.

Download the PDF report

Visit the Interactive Data Page

The report features commentary from ARM’s 2019 Cell & Gene Investor Day:

“I think [in the five-year period] what you’re going to see and what’s really going to be exciting is the innovation and the science, advances in vectorology, advances in understanding how the vector and the host interact with each other to elicit these responses, and perhaps novel approaches to get around some of these immune response issues. I think in the 10-year frame you’re going to see things like a nucleotide base pair editing really starting to take more fruition. […] There are going to be more complex ways to genome editing in the future, to do more sophisticated things, and I think these are the things you’ll start hearing about in the next five to ten years.”

– Mark Kay, M.D., Ph.D., Dennis Farrey Family Professor, Departments of Pediatrics and Genetics; Associate Chair for Basic Research (Pediatrics), Stanford University

“What’s different about our processes for selecting investments is that manufacturing is the most important variable, and to a much greater extent than with any other type of company. The first thing we’re going to ask is, what is your manufacturing set-up? How scalable is it? What can you do yourself? What do you have to outsource? What are you doing in process development today versus what do you need to accomplish tomorrow and how is that vision to commercial scale going to materialize? Manufacturing becomes question one, two, and three when getting to know a gene therapy for the first time.”

– Patrick Rivers, Principal, Aquilo Capital Management